‘
`i
`“
`ROPEAN
`CIETYOF
`
`v
`
`‘
`
`stract Soofiieirjriem‘j‘Augurut/September 2004 rssn 0195-668X
`M
`“
`“m
`‘b IIIIIIIIIII TOWA
`“fl“
`iillillliliiilliililililiiliilliliiiiIliliIiiilliliillilililiilillillli
`__ *
`
`3 1858 050 525 850
`
`European
`Heart Journal
`
`
`
`Journal of the European Society of Cardiology
`
`Liquidia's Exhibit 1007
`Page 1
`
`Liquidia's Exhibit 1007
`Page 1
`
`

`

`European Heart Journal (2004) 25 (Abstract Supplement), xi~xvi
`
`Contents
`
`
`Programme number (P = poster)
`
`Abstract Selection ......................................................................................................
`
`Abstract Review Committee ............................................................................................
`
`Abstracts ..............................................................................................................
`
`Day 2 — Sunday 29 August 2004
`Trends and risk factors in cardiovascular disease .............................................................
`1 17—122
`Risk factors management in prevention .....................................................................
`123—128
`Predictive factors in dilated cardiomyopathy ................................................................
`129—134
`New applications of strain and strain rate imaging ...........................................................
`135—140
`From mice to men: lessons in myocardial protection and hypertrophy ..........................................
`149—154
`Impact of non surgical treatment and physiological stress on the GUCH—heart ..................................
`155—160
`Vascular growth and collateral vessels: opportunities and drawbacks ...........................................
`161—166
`Drug eluting stent in complex lesion subsets ................................................................
`176—181
`Gene variants in hypertension, coronary artery disease and dilated cardiomyopathy .............................
`182—187
`Markers of severity in hypertrophic cardiomyopathy .........................................................
`188—193
`How to perfect coronary artery bypass grafting? .............................................................
`199—204
`Intravascular ultrasound and plaque characterisation .........................................................
`209—214
`Epidemiology and treatment of pulmonary arterial hypertension ..............................................
`215—220
`Revisiting the electrocardiogram and electrophysiologic markers of arrhythmic events ..........................
`221—226
`Nursing aspects of acute cardiac care .......................................................................
`229—234
`Follow-up in the pacemaker and implantable cardioverter—defibrillator Era: old and new issues ...................
`244—249
`Threatening complications with sophisticated devices ........................................................
`250—255
`New risk markers of sudden death after acute myocardial infarction ...........................................
`256—261
`Inotropic intervention: new mechanisms ....................................................................
`275—280
`Muscle wasting and cachexia in heart failure: ready for intervention ...........................................
`281—286
`Percutaneous coronary intervention and beyond for ST—elevation acute myocardial infarction ....................
`304—309
`IIb or not to be in acute myocardial infarction? ..............................................................
`310—315
`P356—P361 Moderated e-Posters I: Cardiac dysfunction: new insights ....................................................
`P362—P377 AtherosclerosisI—BasicScience...................................................................., .....
`P378—P384
`Nuclear cardiology/Magnetic resonance imaging and cardiac radiology .
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`, ......
`P385—P386 Computersincardiology...........................................................................7 ......
`P387—P40l
`Echocardiography/Doppler ................................................................................
`P402—P417
`Atherosclerosis I — Basic Science ..........................................................................
`P418—P424
`Nuclear cardiology/Magnetic resonance imaging and cardiac radiology. .......................................
`P425
`Computers in cardiology ..................................................................................
`P426—P44 1
`Echocardiography/Doppler ................................................................................
`P442—P449 Moderated Poster session I: Arterial hypertension ...........................................................
`P450—P466
`Atrial fibrillation .........................................................................................
`P467—P498 Mechanisms of arrhythmias ...............................................................................
`P499—P540
`Heart failure: clinical aspects ..............................................................................
`P541—P558
`Pulmonary circulation ....................................................................................
`P559—P606
`Thrombosis ..............................................................................................
`P607—P623
`Coronary plaque imaging .................................................................................
`P624—P652
`Endothelial function ......................................................................................
`P653-P682 Myocardial disease .......................................................................................
`683—686
`Computed tomography: Imaging of coronary arteries ........................................................
`688—691
`Young Investigators’ Award Session — Basic Science .........................................................
`693—696
`Young lnvestigators’ Award Session — Thrombosis ..........................................................
`698—701
`Young Investigators’ Award Session — Population Sciences ...................................................
`703—706
`Young Investigators’ Award Session — Clinical Science .......................................................
`729—734
`New prevention strategies .................................................................................
`735—740
`Women, men and cardiovascular disease ....................................................................
`741—746
`Multiple uses of myocardial deformation assessment by echocardiography .....................................
`
`Page
`
`iii
`
`vii
`
`1
`
`3
`4
`6
`7
`9
`10
`12
`13
`15
`16
`18
`19
`21
`22
`24
`25
`27
`28
`30
`31
`33
`34
`36
`37
`41
`43
`44
`48
`52
`53
`54
`58
`6O
`64
`71
`81
`86
`98
`102
`109
`116
`117
`118
`119
`120
`121
`123
`124
`
`Liquidia's Exhibit 1007
`Page 2
`
`Liquidia's Exhibit 1007
`Page 2
`
`

`

`Contents
`xii
`
`
`Communication in vascular smooth muscle cells ............................................................
`747—752
`Oxidative stress and the endothelium .......................................................................
`767—772
`Improving risk stratification by nuclear cardiology ...........................................................
`794—799
`Pathophysiological aspects of resynchronisation therapy .....................................................
`817—822
`Determinants and prevention of post myocardial infarction left ventricular remodelling ..........................
`823—828
`Ablation of atrial fibrillation: from source to success .........................................................
`831—836
`Heart failure with preserved systolic function: whats new? ....................................................
`846—851
`Diagnosis and evaluation of heart failure — still a challenge in the everyday clinical practice ......................
`852—857
`Novel therapeutic strategies in chronic stable angina .........................................................
`876—880
`Dilatedcardiomyopathyorviralmyocarditis?..................................- .............................
`913—918
`P955—P960 Moderated e-Posters II: Brugada syndrome .................................................................
`P961—P976
`Atherosclerosis II — Basic Science .........................................................................
`P977—P983
`Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ........................................
`P984—P985
`Computers in cardiology ..................................................................................
`P986—P1000 Echocardiography/Doppler ................................................................................
`PlOOl—P1016 Atherosclerosis II — Basic Science .........................................................................
`P1017—P1023 Nuclear cardiology/magnetic resonance imaging and cardiac radiology.........................................
`P1024—P1025 Computers in cardiology ..................................................................................
`P1026—P1039 Echocardiography/Doppler ................................................................................
`P1040—P1047 Moderated Poster session 11: Exercise testing ................................................................
`P1048—P1076
`Implantable cardioverter-defibrillator therapy ...............................................................
`P1077—P1096 Ventricular tachycardia ...................................................................................
`P1097—P1148 Heart failure: experimental aspects and risk of inflammation ..................................................
`P1 149—P1 196
`Ischaemia basic aspects ...................................................................................
`P1197—P1225 Non-coronary interventions ...............................................................................
`P1226—P1254 Hypertension ............................................................................................
`P1255—P1276 Valve surgery ............................................................................................
`1277—1280
`Aortic interventions .....................................................- .................................
`
`Day 3 — Monday 30 August 2004
`Endothelial function, oxidative stress and nitric oxide ........................................................
`1300—1305
`Gene expression, contractile function and hypertrophy .......................................................
`1306—1310
`Physical fitness: correlations and determinants ..............................................................
`1312—1317
`Percutaneous interventions in congenital heart disease .......................................................
`1318—1323
`1337—1342 Myocardial perfusion during acute ischaemia: the added value of myocardial contrast
`echocardiography (MCE) .................................................................................
`New aspects of endothelial function related to atherosclerosis .................................................
`1343—1348
`1353—1358 Markers and identification of the vulnerable plaque ..........................................................
`1369—1374
`Protection against ischaemia and ischaemia-reperfusion injury ................................................
`1375—1380
`Frequent unwanted companions: hypertension and hyperlipidaemia ...........................................
`1381—1386
`New horizons in risk stratification of unstable coronary syndromes ............................................
`1399—1403
`Resistance to antiplatelet agents ...........................................................................
`1405—1410
`Intensive treatment for diabetes: key to improved prognosis ...................................................
`1411—1416
`Oral treatment in prevention of in-stent restenosis ...........................................................
`1425—1430
`Atrial fibrillation — clinical presentation risk factors and prognosis ............................................
`1458—1463
`Risk stratification tools in the prediction of coronary events ...................................................
`1469—1474
`Statins in heart failure: friend or foe? .......................................................................
`1475—1480
`Betablockade: new aspects in chronic heart failure ...........................................................
`1496—1501
`Primary percutaneous coronary intervention — special issues ..................................................
`1502—1507
`Evolving concepts in the management of aortic stenosis ......................................................
`1512—1517
`Registries and guidelines in acute coronary syndromes .......................................................
`P1544—P1559 Angiogenic and stem cell therapy — Basic Science ...........................................................
`P1560—P1566 Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ........................................
`P1567—P1568 Computers in cardiology I .................................................................................
`P1569—P1583 Echocardiography/Doppler ................................................................................
`P1584—P1598 Angiogenic and stem cell therapy — Basic Science ...........................................................
`P1599—P1606 Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ........................................
`P1607—P1608 Computers in cardiology ..................................................................................
`Pl609—P1623 Echocardiography/Doppler ................................................................................
`P1624—P1631 Moderated Poster session III: Catheter ablation ..............................................................
`P1632—P1665 Catheter ablation .........................................................................................
`
`126
`127
`129
`130
`132
`133
`135
`136
`138
`139
`141
`142
`146
`147
`148
`152
`156
`157
`l 5 8
`161
`163
`170
`175
`188
`199
`206
`213
`218
`
`223
`224
`225
`227
`
`228
`230
`231
`233
`234
`236
`237
`238
`240
`242
`243
`244
`246
`248
`249
`251
`252
`256
`258
`258
`262
`266
`268
`268
`272
`274
`
`
`
`Liquidia's Exhibit 1007
`Page 3
`
`Liquidia's Exhibit 1007
`Page 3
`
`

`

`
`
`Contents
`
`xiii
`
`P1666—Pl709 Peptides and heart failure .................................................................................
`P1710—P1766 Acute coronary syndromes ................................................................................
`Pl767—Pl811
`Percutaneous coronary intervention ........................................................................
`P1812—P1826 Nursing .................................................................................................
`P1827—P1844 Exercise testing and rehabilitation ..........................................................................
`Pl845—P1871 Hypertension therapeutic aspects ..........................................................................
`1872—1875
`Advanced cardiac imaging ................................................................................
`1929—1934
`Bio-markers of cardiovascular disease ......................................................................
`1935—1940
`Novel magnetic resonance techniques to assess coronary artery disease ........................................
`1941—1945 Mechanisms underlying plaque instability ..................................................................
`1947—1952
`Hormones and cardiac function ............................................................................
`1961—1966
`Clinical and genetic aspects of arrhythmias .................................................................
`1967—1972
`Recent advances in three-dimensional echocardiography .....................................................
`1973—1978
`Ischaemia-reperfusion, slow flow and no reflow .............................................................
`1989—1994
`Computer-based advances in cardiology ....................................................................
`1995—2000
`Vascular and myocardial damage and remodelling ...........................................................
`2001—2006
`Subclinical peripheral artery disease: a marker for severity of coronary artery disease ...........................
`2007—2012
`Stem cells in heart failure .................................................................................
`2026—2031
`Percutaneous interventions in unstable coronary syndromes ..................................................
`2032—2037
`Neurally mediated syncope: a recurrent syndrome revisited ...................................................
`2042—2047
`Novel pharmacological approaches for the treatment of atrial fibrillation .......................................
`2052—2057
`New developments in thrombolysis: fibrinolysis .............................................................
`2087—2091
`A new era in the prognostic assessment of heart failure patients ...............................................
`2097-2102
`New evidence for the beneficial effects of exercise training ...................................................
`2107—21 12
`Primary percutaneous coronary intervention in acute myocardial infarction .....................................
`21 13—21 17 Many things to remember in CABG ........................................................................
`2119—2123
`Exercise testing in mitral valve disease .....................................................................
`2129—2134
`Drug eluting stents in diabetic patients .....................................................................
`2140—2145
`Bad and good habits ......................................................................................
`P2166—P2178
`Stress-induced myocardial damage and protective mechanisms — Basic Science .................................
`P2179—P2185 Nuclear cardiology/MRI and cardiac radiology ..............................................................
`P2186
`Computers in cardiology .
`.- ................................................................................
`P21 87—P2201 Echocardiography/Doppler ................................................................................
`P2202—P2213
`Stress-induced myocardial damage and protective mechanisms ...............................................
`P2214—P2220 Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ........................................
`P2221—P2222 Computers in cardiology ..................................................................................
`P2223—P2237 Echocardiography/Doppler ................................................................................
`P2238—P2245 Moderated Poster session IV: Inflammation and coronary artery disease ........................................
`P2246—P2265
`Pacing ..................................................................................................
`P2266—P2286 Mechanisms of arrhythmias ...............................................................................
`P2287—P2341 Resynchronisation therapy ................................................................................
`P2342—P2409 Acute myocardial infarction and reperfusion therapy .........................................................
`P2410—P2438 Coronary circulation: functional evaluation .................................................................
`P2439—P2484 Epidemiology ............................................................................................
`2485—2488
`Databases and guidelines ..................................................................................
`
`Day 4 — Tuesday 31 August 2004
`Congenital heart disease: secondary challenges after early “repair" ............................................
`2605—2609
`Experimental cell transplantation: preclinical and clinical developments ........’ ...............................
`261 [—2616
`2617—2622 More fuel to inflammation ................................................................................
`2636—2641
`Chronic heart failure: new treatment options ................................................................
`2642—2647
`Oral anticoagulation for atrial fibrillation — still unresolved ...................................................
`2648—2653
`The diabetic vessel .......................................................................................
`2667—2672
`Heart failure news from off the beaten track .................................................................
`2673—2677
`Catheter ablation of ventricular tachycardia .................................................................
`2709—2714
`Diabetes and the heart ....................................................................................
`2725—2730
`Treatment and outcome of acute pulmonary embolism .......................................................
`2768—2773
`Coronary artery disease and renal failure: prognostic aspects and prevention ....................................
`2774—2779
`Clopidogrel loading — 600 mg may be better ................................................................
`2799—2804 Mitral regurgitation: from prognosis to treatment ............................................................
`P2830—P2835 Moderated e-Posters III: Drug therapy in cardiovascular disease ...............................................
`
`282
`292
`306
`317
`321
`325
`332
`333
`334
`336
`337
`339
`340
`342
`343
`345
`346
`348
`349
`351
`352
`354
`355
`357
`358
`360
`361
`362
`364
`365
`368
`370
`370
`374
`377
`379
`379
`383
`385
`390
`395
`408
`425
`432
`443
`
`447
`448
`449
`451
`452
`454
`455
`457
`458
`459
`461
`462
`464
`465
`
`Liquidia's Exhibit 1007
`Page 4
`
`Liquidia's Exhibit 1007
`Page 4
`
`

`

`
`
`Contents
`xiv
`___—________—__—____—.__.———_——_—————-——————
`
`P2836—P2851 Endothelial function, vascular care and remodelling .........................................................
`P2852—P2858 Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ........................................
`P2859
`Computers in cardiology ..................................................................................
`P2860—P2874 Echocardiography/Doppler ................................................................................
`P2875—P2887
`Ion channels and arrhythmias ..............................................................................
`P2888—P2894 Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ........................................
`P2895—P2896 Computers in cardiology ..................................................................................
`P2897—P291 l Echocardiography/Doppler ................................................................................
`P2912—P2919 Moderated Poster session V: Trials in heart failure ...........................................................
`P2920—P2950 Atrial fibrillation .........................................................................................
`P2951—P2995 Heart failure: clinical aspects ..............................................................................
`P2996—P3046 Coronary artery disease in high-risk patients ................................................................
`P3047—P3079 Restenosis and drug-eluting stents .........................................................................
`P3080—P3 123 Risk factor ...............................................................................................
`P3 124—P3 144 Myocardial disease .......................................................................................
`3145—3 148
`Simulation and modelling .................................................................................
`P3265—P3270 Moderated e-Posters IV: Nurse-led interventions in patients with heart failure ..................................
`P3271-P3284 Cardiac hypertrophy and remodelling contractile function — Basic Science .....................................
`P3285—P3291 Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ........................................
`P3292-P3293 Computers in cardiology ..................................................................................
`P3294—P3 308 Echocardiography/Doppler ................................................................................
`P3309—P3323 Cardiac hypertrophy and remodelling contractile function — Basic Science .....................................
`P3324—P3330 Nuclear cardiology/Magnetic resonance imaging and cardiac radiology ........................................
`P3331-P3332 Computers in cardiology ..................................................................................
`P3333—P3347 Echocardiography/Doppler ................................................................................
`P3348—P3354 Moderated Poster session VI: In stent restenosis .............................................................
`P3355—P3374 Electrocardiography ......................................................................................
`P3375—P3394 Syncope ................................................................- .................................
`P3395—P3418 Heart transplantation .....................................................................................
`P3419—P3444 Heart failure — medical therapy ............................................................................
`P3445—P3485 Valvular disease ..........................................................................................
`P3486—P35 12 Coronary artery disease: risk stratification and medical therapy ...............................................
`P3513—P3531
`Stroke ...................................................................................................
`P3532—P3544 Exercise testing and rehabilitation ..........................................................................
`P3545—P3577 Grown-up and congenital heart disease .....................................................................
`P3578—P3588 Coronary artery bypass grafting ............................................................................
`3589—3592
`Databases ...............................................................................................
`
`Day 5 —— Wednesday 1 September 2004
`Pericarditis ..............................................................................................
`3617-3622
`Structure and function of cardiac ion channels ...............................................................
`3627-3632
`Lipid modulation in atherogenesis — beyond cholesterol ......................................................
`3637—3642
`Pulse pressure, distensibility and cardiovascular risk .........................................................
`3643—3648
`Fat, lean or active: all relevant for cardiovascular risk? .......................................................
`3649—3654
`Conduction of the electrical impulse .......................................................................
`3655—3660
`Novel players in receptor-mediated signalling in cardiac myocytes ............................................
`3661—3666
`Nuclear cardiology — beyond the future .....................................................................
`3671—3676
`Challenges in aortic interventions ..........................................................................
`3681—3686
`Stenting of supra-aortic extracranial arteries .................................................................
`3687—3692
`New navigation and mapping techniques for targeting the arrhythmogenic substrate .............................
`3693—3698
`Reducing thrombotic risk — old concepts, new therapies ......................................................
`3703—3708
`Acute myocardial intervention and diabetes .................................................................
`3713—3718
`Pacing mode and lead position: does it matter? ..............................................................
`3723-3728
`How important is abnormal respiration in heart failure? ......................................................
`3729—3734
`New insights into native or repaired mitral valve dynamics ...................................................
`3735—3740
`Renal dysfunction and anaemia — overlooked parts of the heart failure syndrome ................................
`3745—3750
`Ablation of atrial fibrillation: new techniques ...............................................................
`3751—3756
`3757—3762 Management of acute heart failure .........................................................................
`3763—3768 Multiple applications of cardiac computed tomography ......................................................
`3778—3783
`Challenging issues after valve replacement ..................................................................
`3784—3789
`Clinical assessment of resynchronisation therapy ............................................................
`
`467
`471
`472
`473
`476
`479
`481
`482
`485
`488
`495
`506
`519
`527
`537
`543
`544
`545
`548
`550
`55 1
`554
`558
`560
`560
`564
`566
`571
`575
`581
`588
`597
`604
`608
`61 1
`620
`622
`
`627
`628
`630
`631
`633
`634
`636
`637
`638
`640
`641
`643
`644
`646
`647
`649
`650
`652
`653
`654
`656
`658
`
`
`
`Liquidia's Exhibit 1007
`Page 5
`
`Liquidia's Exhibit 1007
`Page 5
`
`

`

`xv
`Contents
`_—.—__—_____________—___
`
`3790—3795
`3801—3806
`38] 1—3816
`3821—3826
`3827—3831
`3833—3838
`3839—3843
`3845—3850
`
`Hypertension and heart failure .............................................................................
`Blood pressure reduction and cardiovascular risk ............................................................
`Heart economics .........................................................................................
`Physical training and secondary prevention .................................................................
`Percutaneous coronary interventions in diabetic patients ......................................................
`Prognostic value of stress echocardiography ................................................................
`Restenosis following bare stents ...........................................................................
`Drug eluting stem to treat in-stent restenosis ................................................................
`
`660
`661
`663
`664
`666
`667
`669
`670
`
`Author Index ..........................................................................................................
`
`673
`
`Index of Topics .........................................................................................................
`
`717
`
`Liquidia's Exhibit 1007
`Page 6
`
`Liquidia's Exhibit 1007
`Page 6
`
`

`

`
` This material may be protected by Copyright law (Title 17 U.S. Code)
`
`
`22
`Epidemiology and treatment ofpulmonary arterial hypertension / The ECG and electrophysiologic markers of arrhythmic events
`
`
`Inhaled treprostinii is a potent pulmonary vasodilator in
`severe pulmonary hypertension
`R. Voswinckel, M.G. Kohstall, B. Enke, T. Gessler, F. Reichenberger,
`H.A. Ghofrani, W. Seeger, H. Olschewski. Medical Clinic 2, Department
`of Internal Medicine, Giessen, Germany
`Background: Treprostinil has been approved for therapy of PAH (US and
`Canada) as continuous subcutaneous infusion. However, local pain at the infu-
`sion site is a major drawback. Inhaled therapy with another stable prostacyclin
`analogue (iloprost) has been approved for PPH (EMEA). In this study we investi-
`gated the acute hemodynamic response to inhaled treprostinii.
`Methods: Open-label, single blind placebo-controlled clinical study. After place-
`ment of a Swan-Gan: catheter and a femoral artery line, patients inhaled solvent
`solution (placebo) (n=8) or treprostinii for 6 min (OptiNeb ultrasound nebulizer.
`Nebu-tec, Germany) in concentrations of 16, 32, 48, and 64 pg/ml (n=6, 6, 6, and
`3 patients). Measurement was performed before and after 0, 15, 30, 60, 90, 120,
`150 and 180 min. The mean area between the placebo and the treprostinii curves
`(ABCfaS) was calculated (baseline=100%).
`Results: We investigated idiopathic PAH (n=10), collagen vascular disease (n=5),
`chronic thromboembolic disease (n=9), and pulmonary fibrosis (n=5), f/m = 19/10,
`
`age 56 :: 3 years, PAP, PAWP, and CVP 51.3 i 2.2, 9.2 i 0.8, and 6.6 i 0.6
`mmHg, CO 4.4 i 0.3 Ilmin, SvO2 62.3 i 1.2%, PVR 885 :i: 72 dyn s cm'5.
`At 16ug/ml there were no significant adverse events. Headache, cough or bron<
`choconstriction were observed in 2, 1, and 2 patients at 32, 48, and 64 jig/ml.
`These were mild and transient in all patients but one (64 jig/ml) who complained
`of major headache for 1 hour. Placebo inhalation was followed by slowly increas-
`ing PVR. Compared to this, the maximum treprostinii effect was reached after
`about 50 min and half-maximal effects at about 110 min. The ABCtBS for PVR
`was —24.7 i 4.4, -28.7 i 4.9, and —29.0 :L- 4.7%; PAP —14.4 d: 3.3, -13.5 :l: 5.2,
`-13.